Loading...
Freedom of Information (FOI) NHS Lothian | Our Organisation
NOTE: 100 recent requests are displayed below. Use search to find older requests.
Freedom of Information Request Reference: 10827
Date Received: 06/11/2025
Summary:
1. Questions 1, 2 and 9. I will follow up with Data Protection team. Regarding Q9, it is simply not true that I was copied into all the emails. I know emails were exchanged between Kenny Scott and Craig Black in early July and I was not copied in. At this time I asked Kenny Scott to forward them to me but he declined. 2. . Question 3. This does not answer my question. I asked specifically and what checks and balances are in place, not whether there are checks and balances are in place. 'Ongoing monitoring' is not a satisfactory answer. What does this mean? What do they actually do? I have now spoken to others in my position and it appears the matter comes to light when they tell payroll and not because payroll unearthed the problem. Regarding eligibility and 2023. It is true SPPA rules changed at this time and some people became eligible to rejoin this particular scheme. However, NHS Lothian's legal duty to auto-enrol these people into an occupational scheme goes back many years before this. The change with the SPPA in 2023, I believe, served primarily as an external catalyst that unearthed people that had missed out for years. 3. Question 4. Perhaps this highlights the need to keep a central records to establish improved administration of the scheme to ensure NHS Lothian is compliant with their legal duties. 4. Question 5. I can do this. 5. Question 6. Does not answer the question have they made people aware. This is rather them being made aware by people affected by the failure to auto- enrol. 6. Questions 7&8. I have subsequently been made aware that it is the Finance Dept that are responsible for such matters so perhaps better these questions are addressed to them. I find it hard to believe there are no guideline/ policies regarding ex gratia and special payments generally if not specific to pensions. One example of such payments might be when an employee incurs bank charges due to a mistake in salary payments by Payroll. Such payments do exist and responsibility is taken in such matters.
Date of Response: 15/12/2025
View Response: 10827.pdf

Freedom of Information Request Reference: 11004
Date Received: 31/12/2025
Summary:
Please can you confirm the below for lung cancer screening programmes in your region/for the population you serve? • Is there a lung cancer screening programme in operation? If more than one, please state. • If applicable, who is the lead NHS organisation for this outside of the ICB/Cancer Alliance? • Is outsourced support from the Independent Sector used?
Date of Response: 22/01/2026
View Response: 11004.pdf

Freedom of Information Request Reference: 10998
Date Received: 05/01/2026
Summary:
Request in relation to medical record.
Date of Response: 05/01/2026
View Response: 10998.pdf

Freedom of Information Request Reference: 10996
Date Received: 05/01/2026
Summary:
How much money over the last 10 years, broken down by year, has your health board given to Stonewall. Please also include the reasons for the payment.
Date of Response: 26/01/2026
View Response: 10996.pdf

Freedom of Information Request Reference: 10993
Date Received: 05/01/2026
Summary:
Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs: •Adalimumab - Humira •Adalimumab Biosimilar •Apremilast •Bimekizumab •Brodalumab •Certolizumab •Deucravacitinib •Dimethyl fumarate •Etanercept - Enbrel •Etanercept Biosimilar •Guselkumab •Infliximab - Remicade •nfliximab Biosimilar •Ixekizumab •Risankizumab •Secukinumab •Tildrakizumab •Ustekinumab - Stelara •Ustekinumab Biosimilar •Omalizumab •Spesolimab Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following: •Adalimumab - Humira •Adalimumab Biosimilar •Bimekizumab •Certolizumab •Infliximab - Remicade •Infliximab Biosimilar •Secukinumab •Ustekinumab - Stelara •Ustekinumab Biosimilar
Date of Response: 26/01/2026
View Response: 10993.pdf

Freedom of Information Request Reference: 10992
Date Received: 05/01/2026
Summary:
Could you please let me know which active primary care rebate schemes your organisation are currently signed up to? Could you please provide the start and end dates of the contracts?
Date of Response: 27/01/2026
View Response: 10992.pdf

Freedom of Information Request Reference: 10988
Date Received: 30/12/2025
Summary:
If, in January 2023, a consultant orthopedic surgeon employed by NHS Lothian was to access x-ray images taken within NHS Tayside in September 2018 - what would be the correct protocol and procedure for doing so? Would any such access to the Picture Archiving and Communication System (PACS) be logged within the NHS Tayside and/or NHS Lothian systems.
Date of Response: 23/01/2026
View Response: 10988.pdf

Freedom of Information Request Reference: 10984
Date Received: 29/12/2025
Summary:
Please could you confirm the below details for all CT and MRI scanners owned by the Trust? Site (location) Modality EOM and scanner model Year of manufacture Designated for
Date of Response: 22/01/2026
View Response: 10984.pdf

Freedom of Information Request Reference: 10983
Date Received: 29/12/2025
Summary:
1.) Please provide the name of NHS Lothian’s organisational process that states that any communication from a patient that allegedly intimates a complaint is to be logged with the Patient Experience Team and that this process does not require the patient’s consent for their data to be passed to the complaints team. 2.) please provide a copy of this process 3.) please provide the date this process was put in place 4.) please explain how this process is communicated to all nhs Lothian staff 5.) please explain how it is made sure that this process is not exploited by staff to the detriment of the patient 6.) please advise where this process is available for patients to view and how they are informed about it 7.) please advise why patients’ consent is not sought for nhs Lothian using their data to submit a complaint on their behalf under this process 8.) please advise what happens to communication addressed to the chief executive of nhs Lothian that was first miscategorised as a complaint by nhs Lothian staff and then was referred back to the chief executive of nhs Lothian for a response. What is considered to be a reasonable time for the chief executive of nhs Lothian to respond to an urgent matter referred to her? 9.) please advise what percentage of those complaint cases that were submitted between 01/06/25 - 24/12/25 to nhs Lothian complaints team suffered a delay in the investigation process and on average how long this delay was.
Date of Response: 26/01/2026
View Response: 10983.pdf

Freedom of Information Request Reference: 10982
Date Received: 29/12/2025
Summary:
1. The number of staff currently recorded by the organisation as belonging to the Armed Forces Community. This includes reservists, veterans, service leavers, cadet force adult volunteers, and staff who have identified as spouses or dependants of serving personnel. 2. The number of staff who have registered with the organisation's Armed Forces Community contact in each of the last three financial years. 3. Any monitoring information, summaries or internal documents produced in the last three financial years that record uptake of Armed Forces related support within the organisation. This includes reservist training leave, Armed Forces related flexible working, or any other support schemes aimed at the Armed Forces Community.
Date of Response: 22/01/2026
View Response: 10982.pdf

Freedom of Information Request Reference: 10981
Date Received: 23/12/2025
Summary:
Could you confirm, in the number of months, the remaining waiting time for adult ADHD assessment in East Lothian, for patients referred for assessment in July 2023, please?
Date of Response: 20/01/2026
View Response: 10981.pdf

Freedom of Information Request Reference: 10980
Date Received: 22/12/2025
Summary:
1. Does your Trust hold a record or inventory of medical-grade freezer units used for the storage of biological, histopathology, research, or biobanking tissue samples? a. If yes, please provide the (a) number of units and (b) storage temperature category (for example -20°C, -80°C) 2. Are any of these freezer units currently used for the rapid freezing and/or long-term storage of brain tissue samples? a. If yes, please state (a) the number of units used for brain tissue and (b) the typical storage temperature used. 3. Regardless of current use, does the Trust have freezer units capable of supporting fresh- or flash- frozen brain tissue storage that is suitable for therapeutic development. a. Does the Trust currently have access to rapid freezing equipment suitable for brain tissue? 4. Only if feasible within the FOI time and cost limit, please indicate whether any existing freezer unit in the Trust could be repurposed or shared between departments to enable brain tissue storage or expand current capacity.
Date of Response: 23/01/2026
View Response: 10980.pdf

Freedom of Information Request Reference: 10979
Date Received: 22/12/2025
Summary:
I am making a request for information under the Freedom of Information (Scotland) Act 2002 in relation to NHS Lothian’s handling and investigation of complaint reference ~~~~~, received on ~~~~~ 2025. This request concerns governance, process, and documentary records relating to the investigation and complaint handling. It does not seek personal medical records. Please provide the following information: 1. Investigation and Decision-Making Roles The professional roles and job titles of individuals involved in: • investigating complaint ~~~~~, • drafting the response issued on ~~~~~ 2025, • drafting the subsequent response issued following the reopening of the complaint, • reviewing, approving, or signing off each response. 2. Staff Accounts Considered Confirmation of which staff members’ accounts were obtained or relied upon during the investigation, including whether accounts were sought from: • the ~~~~~ who was the subject of the complaint, • the ~~~~~ who received the clinical handover, • any other clinical staff involved in the episode of care. 3. Evidence Reviewed A list of the categories of evidence reviewed during the investigation, including: • clinical records, • written patient documentation, • staff accounts, • relevant policies or guidelines. Please confirm whether the written ~~~~~ provided by the complainants was reviewed as part of the investigation. 4. Internal Correspondence Copies of internal correspondence created between ~~~~~ 2025 and the date of the most recent response relating to: • the investigation of complaint ~~~~~, • management of response timescales, • decisions to extend the Stage 2 response timeframe, • the decision to reopen the complaint, • preparation and issue of the further response following reopening. 5. Governance, Risk, or Legal Involvement Confirmation of whether NHS Lothian’s governance, risk, or legal teams were consulted in relation to complaint ~~~~~, including: • the stage or stages at which consultation occurred, • the purpose of that consultation. 6. Timescale Management Records documenting decisions to extend the Stage 2 complaint response timescale beyond 20 working days, including: • dates on which extensions were agreed, • reasons recorded for those extensions. 7. Complaint Handling Guidance Copies of the complaint-handling procedures, guidance, or flowcharts relied upon when managing complaint ~~~~~, including those relating to reopened complaints.
Date of Response: 23/01/2026
View Response: 10979.pdf

Freedom of Information Request Reference: 10974
Date Received: 22/12/2025
Summary:
Under the FOI legislation I would like copies of the CMT team - and management reports iMatter score and action plans for last five years including the most recent one.
Date of Response: 26/01/2026
View Response: 10974.pdf

Freedom of Information Request Reference: 10970
Date Received: 17/12/2025
Summary:
I am looking to verify Contract Start and End Dates to understand framework adherence and competition in the workforce management sector. I am not requesting financial/spend data. Please provide the Provider Name, Contract Start Date, and Contract End Date for the systems listed below. Group 1: Workforce Scheduling • E-Rostering (Medics) • E-Rostering (AHP) • E-Rostering (Nurses) • Bank Technology Platform (Medics) • Bank Management System (Medics) (if not in-house) Group 2: Workforce Planning & Review • Job Planning System (Medics) • Appraisals (Medics) • Multi-Source Feedback (MSF) System (Medics)
Date of Response: 23/01/2026
View Response: 10970.pdf

Freedom of Information Request Reference: 10960
Date Received: 16/12/2025
Summary:
Under the Freedom of Information Act 2000, please provide the following information: 1. For the period 1 January 2024 to 31 December 2024, and separately 1 January 2025 to 31 December 2025 (or, if more readily available, FY 2023/24 and FY 2024/25): • The total number of Plain Radiography (X-ray / plain film) examinations performed by the Trust. 2. For the same period(s), please provide: • The total number of examinations reported externally (outsourced / via teleradiology), broken down by modality where available: o Plain film (X-ray) o CT o MRI o Ultrasound o Other (please specify) • The total expenditure (£) on outsourced radiology reporting services, broken down by supplier. • The names of the suppliers used for outsourced reporting (for example, Everlight, Medica, etc.) and the total amount paid to each supplier. 3. Where available, please include any internal categorisation used by the Trust (for example, urgent vs routine reporting, out-of-hours reporting, or turnaround time bands).
Date of Response: 23/01/2026
View Response: 10960.pdf

Freedom of Information Request Reference: 10941
Date Received: 11/12/2025
Summary:
1. Please provide the total number of advanced practitioners employed in your Trust/Board for each of the years 2021 to 2025. If possible, please break this information down by department or specialty. 2. a)Please could you provide the salary range for advanced practitioners employed in your Trust/Board for each of the years 2021 to 2025. b) Please could you provide the total salary expenditure for advanced practitioners employed in your Trust/Board for each of the years 2021 to 2025. 3. Please could you provide the total number of hours worked by advanced practitioners employed in your Trust/Board for each of the years 2021 to 2025. 4. a) Please could you provide us with any existing documentation which describes the job duties and responsibilities of advanced practitioners within your Trust/Board. b) If not covered in existing documentation, please confirm whether in your Trust/Board advanced practitioners ever i) make referrals to other specialties ii) hold crash / emergency bleeps 5. Within your Trust/Board, please could you tell us a) if advanced practitioners are ever deployed on medical rotas b) if advanced practitioners are permitted to cover doctor rota gaps c) what grade of doctors advanced practitioners are permitted to cover for d) if merged/tiered/general rotas with mixed staffing groups are used and if so, which types and grades of clinicians appear on these rotas. 6. a) Please provide us with a copy of bank shift rotas currently used for all medical and non-medical roles within your Trust/Board b) Please provide us with the current hourly rate-range paid to advanced practitioners working bank shifts in your Trust/Board, broken down by years of service if applicable.
Date of Response: 26/01/2026
View Response: 10941.pdf

Freedom of Information Request Reference: 10939
Date Received: 11/12/2025
Summary:
Q1. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide the total number of patients who received care or clinical attention in corridors or other non-designated clinical areas. Please breakdown by financial year if possible. Q2. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide the total number the total number of hours patients collectively spent receiving corridor care. Please breakdown by financial year if possible. Q3. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide the longest individual recorded duration a patient spent receiving care in a corridor or non-designated area during each year. Please breakdown by financial year if possible. Q4. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide copies of any risk assessments, safety reviews, or incident reports specifically relating to the use of corridor care. Please breakdown by financial year if possible. Q5. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide the total number of patients who presented with Catheter-Associated Urinary Tract Infections (CAUTIs) whilst in your care. Please breakdown by financial year if possible. Q6. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide the total number of patients who presented with Surgical Site Infections (SSIs) whilst in your care. Please breakdown by financial year if possible. Q7. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide the total number of patients who presented with Central Line-Associated Bloodstream Infections (CLABSIs) whilst in your care. Please breakdown by financial year if possible. Q8. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide the total number of patients who presented with Clostridioides difficile (C. diff) Infections) whilst in your care. Please breakdown by financial year if possible. Q9. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide the total number of patients who presented with Methicillin-Resistant Staphylococcus aureus (MRSA) whilst in your care. Please breakdown by financial year if possible.
Date of Response: 23/01/2026
View Response: 10939.pdf

Freedom of Information Request Reference: 10929
Date Received: 09/12/2025
Summary:
Please note, that my questions are in relation to fellowships in Trauma and Orthopaedics only. 1. Do you currently offer, or have you offered in the last year any post CCT (or equivalent) fellowships in trauma and orthopaedics? 2. For each fellowship that you offer, please could you answer/provide the following; a. What is the sub-speciality? b. What was the advertised base pay (or nodal point e.g. MT04, MT05) that the job offers? c. Does the fellowship include being part of an on-call rota, or attract any uplift from the base pay? d. Is that inclusion on the on-call rota optional? e. If yes to question c, please include a copy of the rota, and associated uplift in pay? f. How many annual leave days does this fellowship allow? g. How many study leave days does this fellowship allow? h. What is the study leave budget for the fellowship? i. Please include a copy of the job description and person specification for the job
Date of Response: 27/01/2026
View Response: 10929.pdf

Freedom of Information Request Reference: 10920
Date Received: 09/12/2025
Summary:
Provider 1 1. What is the name of your Admin and Clerical Collaborative Bank software provider? (None if software not used) 2. When did the contract for this provider start? (dd/mm/yyyy) (None if software not used) 3. When does the contract for this provider expire? (dd/mm/yyyy) (None if software not used) Provider 2 (If applicable) 4. What is the name of your second Admin and Clerical Collaborative Bank software provider? (If you have more than one provider) 5. When did the contract for this second provider start? (dd/mm/yyyy) 6. When does the contract for this second provider expire? (dd/mm/yyyy) Provider 3 (If applicable) 7. What is the name of your third Admin and Clerical Collaborative Bank software provider? (If you have more than one provider) 8. When did the contract for this third provider start? (dd/mm/yyyy) 9. When does the contract for this third provider expire? (dd/mm/yyyy) Additional 10. What was the Trust's total spend on Admin and Clerical Collaborative Bank fees in 2024 (excluding implementation)? 11. What was the Trust's total spend on Admin and Clerical Collaborative Bank fees in 2025 (excluding implementation)?
Date of Response: 23/01/2026
View Response: 10920.pdf

Freedom of Information Request Reference: 10760
Date Received: 29/10/2025
Summary:
1. The number of babies born at Simpsons (Edinburgh Royal Infirmary) from 1st October 2024 to 1st October 2025. 2. How many of the babies born in Question 1 were born at less than 27 weeks gestation, or weighed less than 800 grams, or needed multiple intensive care interventions or surgeries.
Date of Response: 27/01/2026
View Response: 10760.pdf

Freedom of Information Request Reference: 10751
Date Received: 28/10/2025
Summary:
1. Among all the children and young people from your health board area who waited in excess of the 18- week CAMHS standard and started their treatment in (a) 2024/25 and b) 2025/26 to date (including those still waiting), what was the total number of days over the 18-week standard that they collectively waited. Please break down the figures for each year specified. For example, if a child began their treatment after 30 weeks, then that child would contribute 84 days towards the total for the year in which they started their treatment (12 weeks x 7 days).
Date of Response: 27/01/2026
View Response: 10751.pdf

Freedom of Information Request Reference: 10973
Date Received: 19/12/2025
Summary:
I would like to submit an FOI request for the number of vials used and patients treated for the following products (see table below) at your trust used in 2025 (total January to December), broken down by brand and size, if possible. If the full-year data is not yet available, you can inform me about the currently available data. Prothrombin Complex Concentrate (PCC) Beriplex Octaplex Prothromplex FEIBA Others (if any please specify) Reversal Agents Ondexxya (andexanet alfa) Praxbind (Idaracizumab) Fibrinogen Concentrate (FC) RiaSTAP FibCLOT Fibryga Others (if any please specify) Fresh Frozen Plasma (FFP) Fresh Frozen Plasma Octaplas Cryoprecipitate Cryoprecipitate Labile Blood Products Whole blood Red blood cells Platelets Factor XIII Fibrogammin
Date of Response: 20/01/2026
View Response: 10973.pdf

Freedom of Information Request Reference: 10972
Date Received: 17/12/2025
Summary:
1.) The number of patients NHS Lothian Primary Care assigned to Annandale Medical Practice, 26 Huntingdon Place, Edinburgh, EH7 4AT in 2025 (01/01/25 - 17/12/25) from out of catchment area. 2.) The number of patients NHS Lothian Primary Care assigned to Annandale Medical Practice, 26 Huntingdon Place, Edinburgh, EH7 4AT in 2024 from out of catchment area. 3.) Is Annandale Medical Practice, 26 Huntingdon Place, Edinburgh, EH7 4AT on NHS Lothian Primary Care's GP practice list that NHS Lothian Primary Care use when NHS Lothian Primary Care assign patients to GP practices from out of catchment area?
Date of Response: 20/01/2026
View Response: 10972.pdf

Freedom of Information Request Reference: 10969
Date Received: 17/12/2025
Summary:
Please answer the following two questions giving numbers for each of the following financial years (i) 2020/21, (ii) 2021/22, (iii) 2022/23, (iv) 2023/24 and (v) 2024/25 1. How many people were (a) treated by your trust where the external cause of them being admitted was recorded as X31 Exposure to excessive natural cold. 2. Of the people referred to in Question 1 how many of them were logged where any of their diagnosis codes (either primary diagnosis or a secondary diagnosis) were (a) any form of pneumonia, or (b) T68 X hypothermia.
Date of Response: 20/01/2026
View Response: 10969.pdf

Freedom of Information Request Reference: 10968
Date Received: 17/12/2025
Summary:
Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which. Q2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following: •Belantamab Mafodotin [Blenrep] •Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone •Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone •Bortezomib [Velcade] ± Dexamethasone •Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd) •Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) •Carfilzomib [Kyprolis] + Dexamethasone •Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) •Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) •Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) •Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) •Daratumumab [Darzalex] monotherapy •Elranatamab •Idecabtagene vicleucel [Abecma] •Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) •Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd) •Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd) •Lenalidomide [Revlimid] + Dexamethasone •Lenalidomide [Revlimid] monotherapy •Panobinostat + Bortezomib + Dexamethasone •Pomalidomide [Imnovid] + Dexamethasone •Selinexor + Bortezomib [Velcade] + Dexamethasone •Selinexor + Dexamethasone •Talquetamab •Teclistamab [Tecvayli] •Any other systemic anti-cancer therapy [please specify] Q3. In the last 6 months, how many patients have been initiated* on the following regimens? •Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) •Carfilzomib [Kyprolis] + Dexamethasone •Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) •Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) •Daratumumab [Darzalex] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Dara-VRd) •Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) •Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) •Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) •Lenalidomide [Revlimid] monotherapy •Lenalidomide [Revlimid] + Dexamethasone •Selinexor + Bortezomib [Velcade] + Dexamethasone •Selinexor + Dexamethasone •Any other systemic anti-cancer therapy [please specify] *Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) during the calendar year 2025 prior to initiation. Q4. In the last 6 months, how many patients have received the following second-line treatment? •Lenalidomide [Revlimid] + Dexamethasone
Date of Response: 20/01/2026
View Response: 10968.pdf

Freedom of Information Request Reference: 10967
Date Received: 17/12/2025
Summary:
1. Do Staff Rest Areas / Break Rooms across NHS Lothian have televisions for staff to utilise whilst on a rest period? 2. Are these TVs required to be covered by a TV Licence? 3. If yes to question number 2, how are these licences paid for? (a) Paid for centrally, by NHS Scotland. (b) Paid for by NHS Lothian. (c) Paid for by the staff who use the break rooms (Such staff Tea Funds, Social Funds etc that are contributed to by individual staff) (d) Other - Please Specify.
Date of Response: 20/01/2026
View Response: 10967.pdf

Freedom of Information Request Reference: 10966
Date Received: 17/12/2025
Summary:
Please can you break down for calendar years 2019, 2020, 2021, 2022, 2023, 2024 and 2025 (up to present date): a) The number of children waiting for the start of treatment via CAHMS b) The longest wait for children starting treatment via CAHMS c) The average wait for children starting treatment via CAHMS
Date of Response: 20/01/2026
View Response: 10966.pdf

Freedom of Information Request Reference: 10964
Date Received: 17/12/2025
Summary:
Regarding the procurement and usage of surgical swabs within your hospital theatres. Specifically, I would like to request the following information: 1. Current Supplier and Contract Details •Who is the current supplier of surgical swabs used in theatre? •What is the scope of the contract (e.g., product types, volumes, duration)? 2. Usage and Procurement •Approximate annual usage volume of surgical swabs in theatre. •List by product group qty, dimension, Qty, Hospital and company provider. •Any guidelines on who should be contacted within procurement 3. Contract Renewal •When is the current contract for surgical swabs due for renewal? •Will the contract be subject to re-tendering, extension, or automatic renewal? 4. Future Planning •Are there any planned changes to procurement strategy for surgical swabs (e.g., moving to framework agreements, sustainability initiatives, or alternative suppliers)?
Date of Response: 20/01/2026
View Response: 10964.pdf

Freedom of Information Request Reference: 10963
Date Received: 17/12/2025
Summary:
How many of completed SAER's have the outcome code Appropriate care, how many is the outcome code indirect system of care issues?
Date of Response: 19/01/2026
View Response: 10963.pdf

Freedom of Information Request Reference: 10962
Date Received: 16/12/2025
Summary:
Q1. Does your health board place a restriction upon the number of dialysis away from base (DAFB) sessions it will cover the cost of within a calendar year within the UK ? If YES: If there are any restrictions in place, please list what these are.
Date of Response: 19/01/2026
View Response: 10962.pdf

Freedom of Information Request Reference: 10961
Date Received: 16/12/2025
Summary:
Please can you provide the following: A) Any documentation that sets of the Health Boards policy in meeting its commitments with the Armed Forces Covenant. B) Confirmation whether the Health Board has a Veterans Network to help veterans seeking access to services. C) For the last five financial years, 2024/25, 2023/24, 2022/23, 2021/22, 2020/21, please provide the cost, if any, of providing services as part of the Health Boards commitment with the Armed Forces Covenant.
Date of Response: 19/01/2026
View Response: 10961.pdf

Freedom of Information Request Reference: 10958
Date Received: 16/12/2025
Summary:
1. The average waiting times for category 5 CT scans between April 2021 to September 2021 for inpatients at Western General Hospital, Crewe Road South, Edinburgh and Royal Infirmary of Edinburgh, 51 Little France Crescent, Old Dalkeith Road, Edinburgh. 2. The average waiting times for CT scans undertaken where there is a suspected bowel perforation for inpatients at Western General Hospital, Crewe Road South, Edinburgh and Royal Infirmary of Edinburgh, 51 Little France Crescent, Old Dalkeith Road, Edinburgh.
Date of Response: 08/01/2026
View Response: 10958.pdf

Freedom of Information Request Reference: 10957
Date Received: 15/12/2025
Summary:
I would please like to know, in each of the last three years for which you have data: 1) The number of staff employed by the trust 2) The total number of days of sick leave taken by staff who took paternity leave in the preceding 12 months 3) The total number of days of sick leave taken by all staff across the trust
Date of Response: 12/01/2026
View Response: 10957.pdf

Freedom of Information Request Reference: 10956
Date Received: 15/12/2025
Summary:
I would be grateful if you could please provide a copy of the Joint Working Arrangements between NHS Lothian and West Lothian Council to ensure that the Integration Joint Board (IJB) is undertaken in accordance with the Public Bodies (Joint Working) (Scotland) Act 2014 and related orders.
Date of Response: 12/01/2026
View Response: 10956.pdf

Freedom of Information Request Reference: 10953
Date Received: 12/12/2025
Summary:
Q1. How many new patients were treated for Asthma by the Trust’s Respiratory Department in the latest 4 month period (August - November 2025) with the treatments I have provided below? Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments either in or before March 2025, they can be classed as a new patient for the purposes of this question. • Cinqaero (Reslizumab) • Dupixent (Dupilumab) • Fasenra (Benralizumab) • Nucala (Mepolizumab) • Tezpire (Tezepelumab) • Xolair (Omalizumab) Q2. How many new patients were treated for Chronic Obstructive Pulmonary Disease (COPD) by the Trust’s Respiratory Department in the latest 4-month period (August – November 2025) with the treatments I have provided below?
Date of Response: 12/01/2026
View Response: 10953.pdf

Freedom of Information Request Reference: 10950
Date Received: 11/12/2025
Summary:
Question One: Will NHS Lothian please state the number of stage two complaints which it received from 1st January 2025 up to and including the 11th November 2025? Question Two: Will NHS Lothian please state the number of complaints, received from the 1st January 2025 up to and including the 11th November 2025, which received a full and final adjudication within the twenty day time limit under stage two of the complaints' procedure?
Date of Response: 13/01/2026
View Response: 10950.pdf

Freedom of Information Request Reference: 10944
Date Received: 11/12/2025
Summary:
I’d like to receive the guidance provided to GPs on gender dysphoric patients that are self-medicating. Specifically on what should be communicated to these patients by their GPs if they request advice on harm reduction basis.
Date of Response: 15/01/2026
View Response: 10944.pdf

Freedom of Information Request Reference: 10912
Date Received: 05/12/2025
Summary:
1. Annual programme budgeting on gynaecology services and procedures. 2. Specific breakdown of expenditure on gynaecology procedures (cervical screenings, laparoscopies, endometrial biopsies, transvaginal ultrasounds). 3. Manuel review of theatre lists for period of 5-7 years, identifying the number of procedures carried out in relation to endometriosis. Including cost per procedure/diagnosis.
Date of Response: 22/01/2026
View Response: 10912.pdf

Freedom of Information Request Reference: 10911
Date Received: 04/12/2025
Summary:
For the financial years 2023/24, 2024/25 and 2025-present, please provide: 1. Whether the Trust currently utilises any clinical insourcing providers to support elective recovery or reduce RTT backlogs. 2. If yes, please list all insourcing providers used during this period, including: o The specialties supported by each provider o Whether the contracts were tendered or directly awarded o The contract start and end dates (or duration) 3. The names or job titles of the individuals or departments responsible for the procurement and management of these insourcing contracts.
Date of Response: 22/01/2026
View Response: 10911.pdf

Freedom of Information Request Reference: 10940
Date Received: 11/12/2025
Summary:
There is no example of a requirement for Masters level qualification being awarded a KTE Band 6 in the NHS Job Evaluation Handbook. However, the KTE Escalator clearly states that " (SCQF 9 or 10) or relevant experience, post reg/graduate diploma or equivalent experience and further post reg/ graduate study (at masters level or above), short courses and/or additional experience" should equate to KTE level 7 (see attached). It is unacceptable that the Executive Director of Nursing makes an unevidenced and untrue statement in a Freedom of Information Response, and I again request written proof if she thinks that a full Masters degree is required (or in any way relevant) to being awarded KTE Level 7, in the written rules of Job Evaluation that NHS Lothian claims to follow. I am sorry that NHS Lothian Freedom of Information is struggling to understand my request and to give me a truthful answer. I suspect it is because there is no evidence for the response #10870 and #9093 statements that I refer to.
Date of Response: 13/01/2026
View Response: 10940.pdf

Freedom of Information Request Reference: 10938
Date Received: 10/12/2025
Summary:
My enquiry is to ask if Lothian NHS is or will be using Palantir software to run our Health Records?
Date of Response: 07/01/2026
View Response: 10938.pdf

Freedom of Information Request Reference: 10937
Date Received: 10/12/2025
Summary:
Please provide, for the most recent 24-month period available: 1. A list of clinical service areas that have seen the greatest increase in demand, based on: o referrals, o waiting lists, or o activity levels. 2. For each of these top 10 areas, please provide: o service name (e.g., mental health, obesity/weight management, sexual health, Vitamin drips and anything else) o percentage increase year-on-year o total number of referrals or attendances (if available) 3. If available, please also provide any internal reports, dashboards or summaries used for monitoring rising demand or service pressures.
Date of Response: 13/01/2026
View Response: 10937.pdf

Freedom of Information Request Reference: 10936
Date Received: 10/12/2025
Summary:
Please could you advise as to whether your organisation has introduced and implemented a policy covering the following: • Supporting Staff with the Installation of Electric Vehicle Charging Infrastructure at their home. • Making a travel claim or any form of reimbursement for charging electrical vehicles at home (Personal or work provided) for the purpose of work-related travel. If so, could you please provide a copy of this policy.
Date of Response: 13/01/2026
View Response: 10936.pdf

Freedom of Information Request Reference: 10935
Date Received: 10/12/2025
Summary:
Q1. How many patients has your Trust treated (for any medical condition) in the past 3 months with the following drugs: • Alprolix • BeneFIX • Haemate P • Idelvion • Refixia • Rixubis • Veyvondi • Voncento • Wilate • Willfact Q2. How many patients have been treated in the past 3 months with: • Marstacimab for Haemophilia B ONLY • Gene therapy for Haemophilia B ONLY • Desmopressin for Von Willebrand Disease ONLY • Tranexamic Acid for Von Willebrand Disease ONLY Q3. Of the patients that were treated with Veyvondi in the past 3 months, how many patients received treatment: • Prophylactically • During surgery • On demand to treat bleeding episodes Q4. Of the patients that were treated with Voncento in the past 3 months, how many patients received treatment: • Prophylactically • During surgery • On demand to treat bleeding episodes Q5. How many patients are registered with your trust for the following diseases: • Haemophilia B • Von Willebrand Disease • Von Willebrand Disease - paediatric patients (age 17 or under)
Date of Response: 13/01/2026
View Response: 10935.pdf

Freedom of Information Request Reference: 10933
Date Received: 10/12/2025
Summary:
For 2024 and 2025 thus far, please supply the following information: 1. The number of hospital admissions with the primary reason for admission being an Eating Disorder (including Anorexia Nervosa, Bulimia Nervosa and EDNOS). 2. Data showing the specific periods of the year in which eating disorder admissions peak (i.e a month by month breakdown of admission numbers).
Date of Response: 16/01/2026
View Response: 10933.pdf

Freedom of Information Request Reference: 10932
Date Received: 10/12/2025
Summary:
1) Your parental leave policies, including paternity leave and pay and maternity leave and pay. If you have different policies for medical and non-medical staff, please include all different policies. 2) In the last three years for which you have data, how many staff members were eligible for paternity leave? 3) In the last three years for which you have data, how many staff members took paternity leave, and for how many weeks on average? 4) In the last three years for which you have data, what was the average salary for staff who were eligible for paternity leave? (If it is not possible to provide this, please provide the average salary for all the trust’s staff instead)
Date of Response: 31/01/2026
View Response: 10932.pdf

Freedom of Information Request Reference: 10931
Date Received: 09/12/2025
Summary:
Section 1: Information about completing this FOI request Who has contributed to filling in this FOI response? Please provide job titles, not names. Were the Play Team and/or Health Play Specialists and/or health play qualified workers involved in compiling the response? [Y/N] Section 2a: FOR ACUTE HOSPITALS ONLY – Information about numbers of wards and beds, and types of play provision Between 1st April 2024 and 31st March 2025, for each hospital that cares for 0-17 year olds, I would like to know information about the numbers of wards/departments and beds that care for 0-17 year olds and the types of play provision. Section 2b: FOR COMMUNITY OR MENTAL HEALTH TEAMS/SETTINGS/SERVICES ONLY – Information about numbers of teams/settings/services, and types of play provision Between 1st April 2024 and 31st March 2025, for each team/setting/service that cares for 0-17 year olds, I would like to know information about the numbers of 0-17 year olds seen and the types of play provision. Section 3a: FOR ACUTE HOSPITALS ONLY – Information about the current Play Team(s) For each hospital that cares for 0-17 year olds, I would like to know information about the current Play Team(s). Also, for each hospital that cares for 0-17 year olds, I would like to know what job titles are within the Play Team(s) and some subsequent information about their roles. Section 3b: FOR COMMUNITY OR MENTAL HEALTH TEAMS/SETTINGS/SERVICES ONLY – Information about the current health play professionals For each team/setting/service that cares for 0-17 year olds, I would like to know information about the current health play professionals. Also, for each team/setting/service that cares for 0-17 year olds, I would like to know what health play job titles there are and some subsequent information about their roles. Section 4: Information about recruiting the Play Team(s)/health play professionals For each hospital OR team/setting/service that cares for 0-17 year olds, I would like to know information about recruiting the Play Team(s)/health play professionals. Section 5a: FOR ACUTE HOSPITALS ONLY – Information about play coverage For each hospital that cares for 0-17 year olds, I would like to know about the play coverage in terms of hours/times of day. Do you have any other measures/provisions that make this hospital or ward/department more welcoming or playful for children and young people before attending an appointment/being admitted? [Y/N] If yes, please tell us what these measures/provisions are. Do you have any other measures/provisions that make this hospital or ward/department more welcoming or playful for children and young people during their appointment/admission? [Y/N] If yes, please tell us what these measures/provisions are. Section 5b: FOR COMMUNITY OR MENTAL HEALTH TEAMS/SETTINGS/SERVICES ONLY – Information about play coverage For each team/setting/service that cares for 0-17 year olds, I would like to know about the play coverage in terms of hours/times of day. Do you have any other measures/provisions that make that team/setting/service more welcoming or playful for children and young people before attending an appointment/being admitted? [Y/N] If yes, please tell us what these measures/provisions are. Do you have any other measures/provisions that make that team/setting/service more welcoming or playful for children and young people during their appointment/admission? [Y/N] If yes, please tell us what these measures/provisions are. Section 6a: FOR ACUTE HOSPITALS ONLY – Information about play budgets For each hospital that cares for 0-17 year olds, I would like to know information about the annual budget for play. If you answered ‘Yes’ or ‘No but resources can be purchased through a central budget’, I would also like to know what the annual budget was for play in healthcare in FY24-25 (between 1st April 2024 and 31st March 2025) and what it was spent on. Also, for each hospital that cares for 0-17 year olds, I would like to know who funds the budget for play staff / resources (e.g., ICB, Health Board, Charity, a Fundraising Group, other donations, etc.). Section 6b: FOR COMMUNITY OR MENTAL HEALTH TEAMS/SETTINGS/SERVICES ONLY – Information about play budgets For each team/setting/service that cares for 0-17 year olds, I would like to know information about the annual budget for play. If you answered ‘Yes’ or ‘No but resources can be purchased through a central budget’, I would also like to know what the annual budget was for play in healthcare in FY24-25 (between 1st April 2024 and 31st March 2025) and what it was spent on. Also, for each team/setting/service that cares for 0-17 year olds, I would like to know who funds the budget for play staff / resources (e.g., ICB, Health Board, Charity, a Fundraising Group, other donations, etc.). Section 7: Information about the Play Well Toolkit For each hospital OR team/setting/service that cares for 0-17 year olds, I would like to know information about the Play Well Toolkit. Section 8: Information about measurement tools for 0-17 year olds For each hospital OR team/setting/service that cares for 0-17 year olds, I would like to know information about measurement tools.
Date of Response: 14/01/2026
View Response: 10931.pdf

Freedom of Information Request Reference: 10930
Date Received: 09/12/2025
Summary:
1. The number people in Scotland (NHS Lothian) requiring NHS medical treatment following complications from a non surgical injectable aesthetic procedure carried out in Scotland outwith an NHS or HIS registered clinic. 2. The number people in Scotland (NHS Lothian) requiring NHS medical treatment following complications from a non surgical injectable aesthetic procedure carried out in a clinic or other outwith the United Kingdom.
Date of Response: 16/01/2026
View Response: 10930.pdf

Freedom of Information Request Reference: 10928
Date Received: 08/12/2025
Summary:
1. Patient Waiting Times (As of December 2025) What are the total number of patients currently waiting for a routine or urgent-suspected-cancer MRI scan, broken down by the following waiting time periods from referral date to scan date: a) Under 6 weeks b) 6 to under 8 weeks c) Over 8 weeks? 2. Urgent Referral Waiting Times (Last Quarter) What was the average and maximum waiting time (in days) for an urgent referral for an MRI scan for the last full quarter (i.e. July 2025 – September 2025)? 3. Scanner Operation and Downtime (Last 12 Months) For the last 12 months (e.g. December 2024 – November 2025): a) What was the average daily operational rate (in hours) for each fixed NHS MRI scanner managed by the Health Board? b) What was the total unplanned downtime (in days) for each fixed NHS MRI scanner due to maintenance, repair, or breakdown? 4. MRI Scanner Asset List (Current) Please provide a list of all operational MRI scanners currently managed by the Health Board, including a) The model name/number b) The year of purchase (or commissioning date) c) The date of installation. 5. Average Cost of Scan (Last Financial Year) What was the average Health Board cost for performing a single MRI scan for the last complete financial year (2024/25)? Please specify the key cost components included in this figure (e.g., staff, maintenance, consumables, depreciation). 6. Outsourcing Costs (Last Financial Year) What was the total annual cost for the Health Board on outsourcing MRI scans to private providers in the last complete financial year (2024/25)?
Date of Response: 09/01/2026
View Response: 10928.pdf

Freedom of Information Request Reference: 10927
Date Received: 09/12/2025
Summary:
How many patients were treated in the last 6-month period with branded or generic emtricitabine / tenofovir disoproxil fumarate (Truvada) for HIV treatment? How many patients were treated in the last 6-month period with branded or generic emtricitabine / tenofovir disoproxil fumarate for Pre-exposure prophylaxis (PrEP)? How many packs of branded or generic emtricitabine / tenofovir disoproxil fumarate were dispensed in latest 6-month period for HIV treatment? How many packs of branded or generic emtricitabine / tenofovir disoproxil fumarate were dispensed in latest 6-month period for Pre-exposure prophylaxis (PrEP)? How many patients were treated in the last 6-month period with tenofovir alafenamide / emtricitabine (Descovy) for HIV treatment? How many patients were treated in the last 6-month period with tenofovir alafenamide / emtricitabine for Pre-exposure prophylaxis (PrEP)? How many packs of tenofovir alafenamide / emtricitabine were dispensed in latest 6-month period for HIV treatment? How many packs of tenofovir alafenamide / emtricitabine were dispensed in latest 6-month period for Pre-exposure prophylaxis (PrEP)?
Date of Response: 12/01/2026
View Response: 10927.pdf

Freedom of Information Request Reference: 10926
Date Received: 09/12/2025
Summary:
Subsequent to Scottish Medicines Consortium (SMC) guidance SMC2497 09/10/2023 and SMC2653 10/06/2004, please provide information on whether your board has: 1. Developed a protocol for the use of the drugs Semaglutide or Tirzepatide for the treatment of Metabolic dysfunction Associated Steatotic Liver Disease (MASLD) in line with the above guidance if so, please supply a copy of this, along with the date it was produced 2. If a protocol has been developed, please confirm if it has been implemented, and if so, provide the date on which it was implemented 3. Please provide numbers of patients who subsequent to SMC guidance cited above, have commenced either drug for the treatment of MASLD in your health board up until 1st of October 2025
Date of Response: 12/01/2026
View Response: 10926.pdf

Freedom of Information Request Reference: 10924
Date Received: 08/12/2025
Summary:
The average waiting time for a patient to be seen by NHS Lothian’s Ophthalmology Service, following a routine referral from an optometrist due to a suspicion of keratoconus, in December 2020.
Date of Response: 09/01/2026
View Response: 10924.pdf

Freedom of Information Request Reference: 10923
Date Received: 09/12/2025
Summary:
Can I request any AfC staff policy you have for on call working arrangements please?
Date of Response: 31/12/2025
View Response: 10923.pdf

Freedom of Information Request Reference: 10922
Date Received: 09/12/2025
Summary:
I am trying to obtain a complete list of all NHS dental clinics registered under Lothian, along with the dentists currently working in each clinic.
Date of Response: 08/01/2026
View Response: 10922.pdf

Freedom of Information Request Reference: 10921
Date Received: 09/12/2025
Summary:
Provider 1 1. What is the name of your AHP Direct Engagement software provider? (None if software not used) 2. When did the contract for this provider start? (dd/mm/yyyy) (None if software not used) 3. When does the contract for this provider expire? (dd/mm/yyyy) (None if software not used) Provider 2 (If applicable) 4. What is the name of your second AHP Direct Engagement software provider? (If you have more than one provider) 5. When did the contract for this second provider start? (dd/mm/yyyy) 6. When does the contract for this second provider expire? (dd/mm/yyyy) Provider 3 (If applicable) 7. What is the name of your third AHP Direct Engagement software provider? (If you have more than one provider) 8. When did the contract for this third provider start? (dd/mm/yyyy) 9. When does the contract for this third provider expire? (dd/mm/yyyy) Additional 10. What was the Trust's total spend on AHP Direct Engagement fees in 2024 (excluding implementation)? 11. What was the Trust's total spend on AHP Direct Engagement fees in 2025 (excluding implementation)?
Date of Response: 09/01/2026
View Response: 10921.pdf

Freedom of Information Request Reference: 10919
Date Received: 09/12/2025
Summary:
• Do you commission a specialist weight management service? Is it located within your catchment area? If not, where are people within your area requiring specialist weight management services typically referred? • If you commission a specialist weight management service, is it currently accepting new referrals? And if it is not accepting new referrals, when did this come into effect? • Does the specialist weight management service you commission prescribe GLP-1RA weight loss drugs? And if yes, does this include the following (please specify all those it includes): o Liraglutide (Saxenda®) o Semaglutide (Wegovy®) o Tirzepatide (Mounjaro®) • If yes, how many patients have been prescribed a GLP-1RA for weight loss through the service you commission? • If the service does not prescribe GLP-1RAs, is there a planned start date for when the services may begin prescribing GLP-1RAs for weight loss? • Do you fund bariatric surgery for people living in your catchment area? • Please list all the current criteria that are used for funding decisions regarding bariatric surgery - for example, but not limited to, BMI cut-offs, type 2 diabetes status, time in weight management service, requirement for preoperative weight loss, comorbidities etc. • Is there a commissioned/designated bariatric surgery service located within your catchment area? If not, where are people requiring bariatric surgery within your area typically referred?
Date of Response: 12/01/2026
View Response: 10919.pdf

Freedom of Information Request Reference: 10917
Date Received: 08/12/2025
Summary:
Q1. Within your trust, how many patients currently have a diagnosis for: • Fabry(-Anderson) disease (ICD10 code E75.21) • Gaucher disease (ICD10 code E75.22) • Pompe disease (ICD10 Code E74.02) • Pompe disease (ICD10 Code E74.02) infantile onset (patients diagnosed before age 1) • Hunter syndrome (MPS II) (ICD10 code E76.1) Q2. Of the patients above, how many patients have been newly diagnosed within the past 3 months for: • Fabry(-Anderson) disease (ICD10 code E75.21) • Gaucher disease (ICD10 code E75.22) • Pompe disease (ICD10 Code E74.02) • Pompe disease (ICD10 Code E74.02) infantile onset (patients diagnosed before age 1) • Hunter syndrome (MPS II) (ICD10 code E76.1) Q3. How many patients have been treated in the last 3 months with the following products: • Replagal (agalsidase alfa) • Fabrazyme (agalsidase beta) • Galafold (migalastat) • Elfabrio (pegunigalsidase alfa) • VPRIV (velaglucerase alfa) • Cerezyme (imiglucerase) • Cerdelga (eliglustat) • Zavesca (miglustat) • Myozyme (alglucosidase alfa) • Nexviadyme (avalglucosidase alfa) • Pombiliti + Opfolda (cipaglucosidase alfa/miglustat) Q4. Do you participate in any clinical trials for Fabry(-Anderson) disease? If so, can you please provide the name of each trial along with the number of patients taking part? Q5. Do you participate in any clinical trials for Gaucher disease? If so, can you please provide the name of each trial along with the number of patients taking part?
Date of Response: 09/01/2026
View Response: 10917.pdf

Freedom of Information Request Reference: 10915
Date Received: 08/12/2025
Summary:
I am writing with a Freedom of Information request regarding your Health Board's use of recruitment agencies. I would like to receive data on: 1. The current number of executives, managers, and clinical staff employed by your Health Board (separately for each staff category) 2. The number of executives, managers, and clinical staff hired by your Health Board using a recruitment agency in each of the last 5 fiscal years, separately for each staff group 3. The annual staff turnover rate for each staff group over the last 5 fiscal years
Date of Response: 19/01/2026
View Response: 10915.pdf

Freedom of Information Request Reference: 10914
Date Received: 05/12/2025
Summary:
I am writing to request a detailed breakdown of Medical Agency spend for the following periods: • 1st April 2024 – 31st March 2025 • 1st April 2025 – 31st October 2025
Date of Response: 07/01/2026
View Response: 10914.pdf

Freedom of Information Request Reference: 10910
Date Received: 04/12/2025
Summary:
I am interested to know how the money that was allocated for annual health checks for people with learning disabilities is being spent. Please provide the following information: 1. Confirmation that the money allocated to provide these checks each year from the Scottish Government has been spent exclusively on that purpose. If not, please reveal what other health areas it has been spent on. 2. Please provide a breakdown of the total amount of money allocated to the board by the government each year the funding has been given. Please break this down by financial year. Please also reveal the total amount of the money that was spent. Please also reveal in % terms of how much of the money has been spent. 3. If the annual health check funding has been transferred to other budgets or has been spent for other purposes in each year, then please provide a breakdown of the amounts that were spent and for what purpose. 4. Reveal the number of patients the board is aware of who are eligible for a check but has never received one to date. In other words, how many people since the policy was announced in 2022 have been eligible for one but has yet to receive their first check. Please also reveal how many people that is out of the total amount of eligible people. [people who have and who not received one]. 5. Please provide a copy of the last piece of correspondence the board has had with the Minister for Social Care Tom Arthur on annual health checks for people with learning disabilities.`
Date of Response: 06/01/2026
View Response: 10910.pdf

Freedom of Information Request Reference: 10908
Date Received: 04/12/2025
Summary:
1. Staff use of pronouns o How many staff currently include pronouns in their official work email signatures? o If exact numbers aren’t held, please provide any monitoring, estimates, or internal data you have. 2. Organisational position o Is the inclusion of pronouns in email signatures mandated, encouraged, or left entirely optional within your organisation? o Please provide any policies, internal guidance, or communications that set out your approach. 3. References to external resources o How many staff include a link to pronouns.org (or similar websites) in their email signatures or internal profiles? o Does your organisation promote, endorse, or direct staff toward pronouns.org or similar guidance? Does your organisation endorse the content of pronouns.org? o Please share any documents, training materials, or communications that reference or recommend this website. 4. Internal communications and staff responses o Please provide copies of any communications or briefings sent to staff regarding the use of pronouns in email signatures. o Has your organisation received any objections, complaints, or concerns from staff in relation to pronoun guidance or expectations? o If so, please provide the number of cases and any summaries you hold, including whether any issues were raised by staff with gender-critical beliefs or staff citing religious beliefs. 5. Impact considerations o Have any Equality Impact Assessments or similar assessments been carried out regarding your organisation’s approach to pronoun use? o If so, please provide copies or summaries of these assessments.
Date of Response: 07/01/2026
View Response: 10908.pdf

Freedom of Information Request Reference: 10907
Date Received: 04/12/2025
Summary:
Could you please answer the questions below: Q1. How many patients have been treated (for any condition) in the last 4 months with: •Benralizumab •Dupilumab •Omalizumab •Reslizumab •Mepolizumab •Tezepelumab Q2. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with: •Dupilumab •Omalizumab Q3. How many patients have been treated in the last 4 months for Chronic Obstructive Pulmonary Disease (COPD) with: •Dupilumab •Mepolizumab
Date of Response: 06/01/2026
View Response: 10907.pdf

Freedom of Information Request Reference: 10905
Date Received: 03/12/2025
Summary:
I wish to make a Freedom of Information Request for the number of code nines (code black) declared in 2020, 2021, 2022, 2023, 2024 & 2025 to the present date. With a breakdown of each year.
Date of Response: 16/01/2026
View Response: 10905.pdf

Freedom of Information Request Reference: 10855
Date Received: 18/11/2025
Summary:
In follow up to our previous freedom of information request (Management of patients with ASCVD and Lipoprotein(a) testing’) submitted in December 2024, please could we submit the following additional questions regarding lipoprotein(a) (Lp(a)) testing at you organisation. Question 1: Does NHS Lothian test patients for raised levels of lipoprotein(a)? Yes No Question 2: Does NHS Lothian have any guidelines or policies for the treatment of patients diagnosed with elevated* levels of lipoprotein(a)? *Elevated Lp(a) defined as >90 nmol/L. Yes/No If Yes, please provide a copy.
Date of Response: 19/01/2026
View Response: 10855.pdf

Freedom of Information Request Reference: 10790
Date Received: 03/11/2025
Summary:
In every year since 2020/21, in maternity units in your health board, how many errors regarding venous thromboembolism risk assessments and medication have there been?
Date of Response: 19/01/2026
View Response: 10790.pdf

Freedom of Information Request Reference: 10901
Date Received: 02/12/2025
Summary:
Could you please tell me how many adult ADHD assessments have been carried out by Lothian (in particular Mid-Lothian) in the past three years and how long one could expect to wait before being contacted.
Date of Response: 05/01/2026
View Response: 10901.pdf

Freedom of Information Request Reference: 10900
Date Received: 01/12/2025
Summary:
1. Does the Trust have a designated lead responsible for patient flow/navigation, or for reducing non-necessary A&E admissions? (This may include roles linked to Single Points of Access, Flow Navigation Centres, etc.) If so, please provide: o Name o Job title o Division/department 2. Does the Trust currently operate any live initiatives or programmes aimed at reducing A&E admissions? If yes, please provide a brief outline of these initiatives.
Date of Response: 13/01/2026
View Response: 10900.pdf

Freedom of Information Request Reference: 10896
Date Received: 28/11/2025
Summary:
This relates specifically to community nursing and post registration qualifications to support career development. 1. Please provide the number of nurses employed by the NHS Board who were funded by the NHS Board to start community nursing qualifications each year from 2020 to 2025 to date: Specialist Practitioner Qualification (SPQ) District Nursing Specialist Community Public Health Nursing (SCPHN) Health Visiting qualification Specialist Community Public Health Nursing (SCPHN) School Nursing qualification 2. Please provide the number of nurses employed by the NHS Board who completed community nursing qualifications each year from 2020 to 2025 to date: Specialist Practitioner Qualification (SPQ) District Nursing Specialist Community Public Health Nursing (SCPHN) Health Visiting qualification Specialist Community Public Health Nursing (SCPHN) School Nursing qualification Community Nursing (Graduate Diploma) Community Nursing (Graduate Certificate) 3. For district nursing staff employed by the NHS Board please provide: a. Number (headcount) by each Agenda for Change at Band 5 and above with the following qualifications • Specialist Practitioner Qualification (SPQ) District Nursing • Community Nursing (Graduate Diploma) • Community Nursing (Graduate Certificate) b. Number of district nursing staff (headcount) by each Agenda for Change Band at Band 5 and above 3a) Specialist Practitioner Qualification (SPQ) District Nursing Community Nursing (Graduate Diploma) Community Nursing (Graduate Certificate) b) District nursing staff (headcount) 4. For health visiting staff employed by the NHS Board please provide: a. Number (headcount) by each Agenda for Change at Band 5 and above with the following qualifications • Specialist Community Public Health Nursing (SCPHN) Health Visiting qualification • Community Nursing (Graduate Diploma) • Community Nursing (Graduate Certificate) b. Number of health visiting staff (headcount) by each Agenda for Change band at Band 5 and above 4a) Specialist Community Public Health Nursing (SCPHN) Health Visiting qualification Community Nursing (Graduate Diploma) Community Nursing (Graduate Certificate) b) Health visiting staff (headcount) 5. For school nursing staff employed by the NHS Board please provide: a. Number (headcount) by each Agenda for Change at Band 5 and above with the following qualifications • Specialist Community Public Health Nursing (SCPHN) School Nursing qualification • Community Nursing (Graduate Diploma) • Community Nursing (Graduate Certificate) b. Number (headcount) of school nursing staff by each Agenda for Change at Band 5 and above 5a) Specialist Community Public Health Nursing (SCPHN) School Nursing qualification Community Nursing (Graduate Diploma) Community Nursing (Graduate Certificate) b) School nursing staff (headcount) 6. We have considered community qualifications in light of the range of nursing in the independent health and social care sector, such as care homes and general practice. We would however specifically like to hear from the NHS Board in relation to prison nurses employed by the NHS Board. Please provide the number of nurses working in prisons who are employed by the NHS Board who completed a) the Community Nursing (Graduate Diploma) and b) Community Nursing (Graduate Certificate) in the years outlined in the table. Community Nursing (Graduate Diploma) Community Nursing (Graduate Certificate) 7. Does the NHS Board have designated General Practice Nursing lead post(s)? If Yes, please provide the a. number of posts b. whole time equivalent (WTE) c. job title(s) d. and if staff are currently in post. 8. Does the board have Nurse Consultant post(s) for community nursing? i) If Yes, please provide the a. number of posts b. whole time equivalent (WTE) c. job title(s) d. and if staff are currently in post ii) If there are no current Nurse Consultant post(s) in community nursing, are these role(s) being considered by the NHS Board?
Date of Response: 31/12/2025
View Response: 10896.pdf

Freedom of Information Request Reference: 10893
Date Received: 27/11/2025
Summary:
General Department Information · How many inpatient orthopaedic beds does your department have? · What is your average length of stay for orthopaedic patients? · Do you have a dedicated orthopaedic ward, or are patients placed in mixed-specialty wards? Patient Journey Information · What's the average wait in ED before ward transfer? · Do they remain on trolleys throughout ED stay or transferred onto beds? · What mattress do the ED trolleys have? · When does Pressure Area Care start? · What is the average time to get to Theatre? · What kind of Table is used in Theatre? · How quickly are the patients mobilised post operatively? Staffing & Roles · What is your nurse-to-patient ratio during day and night shifts? · Do you have a dedicated Tissue Viability Nurse (TVN) or team? · Are healthcare support workers trained in pressure area care? · Do you have a multidisciplinary team involved in pressure damage prevention (e.g., physiotherapists, occupational therapists)? Equipment & Resources · What type of pressure-relieving equipment is routinely used (mattresses, cushions, boots)? · Do you use any specific technology or tools to assess pressure damage risk (pressure mapping, skin assessment tools)? · What type of beds are used? · How often are pressure-relieving devices audited or maintained? Policies & Protocols · What is your protocol for pressure area assessment on admission and during the inpatient stay? · How frequently are skin assessments carried out? · Do you use a specific risk assessment tool Waterlow, PUDDRA)? · What is your escalation process when pressure damage is identified? · Do you have a formal pressure ulcer prevention strategy or pathway? Data & Outcomes · What is your current rate of hospital-acquired pressure damage in orthopaedic inpatients? · How is pressure damage data collected and reported? · Do you conduct regular audits or quality improvement projects related to pressure damage? · Have you implemented any recent changes that have positively impacted pressure damage rates? Education & Training · What training do staff receive on pressure damage prevention and management? · How often is this training updated or refreshed? · Do you provide patient education on pressure damage prevention? Patient Education & Engagement · Do you provide pressure damage prevention education to patients upon admission? If so, what does it include? · Are patients given written or digital materials about pressure area care? · Is patient education tailored to specific risk groups (e.g., elderly, post-op, immobile)? · How do you ensure patients understand and engage with pressure damage prevention strategies? · Do you involve family members or carers in pressure damage education? · Are patients encouraged to participate in their own pressure area care (e.g., repositioning, skin checks)? · Do you use any visual aids, videos, or interactive tools to support patient education? · Is patient education documented in the care plan or nursing notes? · Do you audit or evaluate the effectiveness of your patient education on pressure damage prevention?
Date of Response: 31/12/2025
View Response: 10893.pdf

Freedom of Information Request Reference: 10887
Date Received: 26/11/2025
Summary:
Please can I get a copy of your latest Rapid tranquillisation or management of acute disturbance policy/guidance?
Date of Response: 07/01/2026
View Response: 10887.pdf

Freedom of Information Request Reference: 10890
Date Received: 26/11/2025
Summary:
I am keen to understand the Scottish Government’s engagements with NHS Boards in relation to winter preparedness planning and the Scottish Government’s surge and winter preparedness in health and social care services national planning priorities and principles. As such, can I request the following from your board: • A copy of the health board’s 2025 operational surge and winter preparedness plan. • Has the health board submitted its 2025 operational surge and winter preparedness plan to the Scottish Government? If so, on which date did they submit this? • Was a deadline set for health boards to submit their plans to the Scottish Government? If so, when was it set, how long did the health board have to submit plans. and what was the deadline date to submit plans? • On which date did health boards receive the Scottish Government’s surge and winter preparedness in health and social care services national planning priorities and principles?
Date of Response: 13/01/2026
View Response: 10890.pdf

Freedom of Information Request Reference: 10871
Date Received: 21/11/2025
Summary:
Under the Freedom of Information Act, please could you provide the following information regarding undergraduate medical psychiatry training funding at your Trust/Health Board: 1.Please state how many student ‘places’ the Trust/Health Board hosted over the last financial year (24-25). Please state: o Please specify which medical schools you hosted students from and how many students from each medical school were hosted. 2.Does your Trust/Health Board receive a specific allocation of funding for undergraduate medical psychiatry training? Yes No If yes, please provide the amount received for the last financial year. Please state: o Please specify how much of this funding is from any of the following sources (this will depend on your location within the UK): Medical Education Tariff Additional Cost of Teaching (ACT) Healthcare Education and Training Tariff (HETT) Supplement for Undergraduate Medical and Dental Education (SUMDE) Other sources, please state: 3.Is the funding ring-fenced specifically for undergraduate medical psychiatry training? Yes No If it is not ring-fenced, how is the use of funds monitored? Please state: 4.Does the Trust/Health Board maintain specific accounts/records of how undergraduate psychiatry training funds are spent? Yes No a. Could you provide breakdown of expenditure categories? Yes No If yes, please select which categories: Teaching Staff time Educational facilities Placements Administrative Costs b. Do you employ clinical teaching fellows/similar posts and administrative staff directly for undergraduate medical education, using the undergraduate funds? Yes No If the Trust/Health Board has made notable expenditures on medical undergraduate education in the most recent financial year that have not been listed in response to question 4, please provide this information: 5.Does the Trust/Health Board use a reporting tool to account for these funds? Yes No c. If not, how is this information reported or monitored? d. Are these reports available for public viewing? Yes No
Date of Response: 09/01/2026
View Response: 10871.pdf

Freedom of Information Request Reference: 10851
Date Received: 17/11/2025
Summary:
Please provide the following information for the period 3 July 2023 to the present day (or nearest available date): 1. A list of all suppliers that were actually contracted, engaged, or utilised by NHS Lothian under the NHS SBS “Insourcing of Clinical Services” Framework (SBS10203). Please note: I am not seeking the publicly available list of approved suppliers, but only those suppliers whose services were actually used by NHS Lothian in this timeframe. 2. For each supplier identified, please provide: The total spend on services provided by the supplier (including invoices issued but not yet paid), ideally broken down by month, though any available format is acceptable. The service or specialty the supplier was engaged to deliver. 3. For each supplier, please also provide the following information if it is held by NHS Lothian: The rate agreed or amount paid per session, per day, or per case for insourcing activity. Any information held by NHS Lothian on the breakdown of these payments, specifically: the portion paid to the clinician(s) delivering the work versus the portion retained by the agency (fees, margin, administrative charges)
Date of Response: 05/01/2026
View Response: 10851.pdf

Freedom of Information Request Reference: 10959
Date Received: 16/12/2025
Summary:
Please provide recorded information held by NHS Lothian within the last 18 months that confirms: 1. Whether a change to the Advanced Nurse Practitioner (ANP) uniform has been approved, planned, or formally proposed; and 2. If a change has been approved or is planned, details of: o What the new or replacement uniform will be, and o The anticipated or agreed implementation timeframe; and 3. If no change is planned, confirmation of this and the most recent recorded decision stating that no change will be made.
Date of Response: 31/12/2025
View Response: 10959.pdf

Freedom of Information Request Reference: 10897
Date Received: 01/12/2025
Summary:
I would be grateful if you could provide copies of any internal guidelines, protocols, policies or standard operating procedures that relate specifically to mealtime/ dining room support in the treatment of eating disorders within your services. This includes, but is not limited to, documents that cover: • expectations and roles of staff during mealtimes • levels of supervision and support before, during and after meals or snacks • management of meal related distress, behaviours or incidents • use of any structured mealtime programmes or approaches • Nasogastric feeding or the use of oral nutrition supplements If different guidelines are used in different settings, please provide all relevant documents. For example, where your organisation has separate or adapted guidance for: • inpatient wards • day hospital or day programme services • intensive outpatient / intensive community treatment • outpatient or community services Similarly, I would also be grateful if you could provide all protocol versions, if different protocols apply to different age groups, including: • adult eating disorder services • CAMHS / children and young people’s eating disorder services • all age or transition services, if applicable
Date of Response: 31/12/2025
View Response: 10897.pdf

Freedom of Information Request Reference: 10976
Date Received: 22/12/2025
Summary:
I'm writing to request some information under the Freedom of Information (Scotland) Act 2002 regarding the vehicles currently in use by Lothian NHS Scotland, For each vehicle, please provide the following information: -Vehicle Make/model and body colour -Date of first registration with the DVLA (in format DD/MM/YYYY) -Date of the next MOT in format DD/MM/YYYY (where applicable - I am aware that vehicles under three years old are exempt from MOT testing)
Date of Response: 24/12/2025
View Response: 10976.pdf

Freedom of Information Request Reference: 10925
Date Received: 09/12/2025
Summary:
Could you please provide the antenatal CTG guidance in place currently, as well as in August 2022? The guidance should cover CTGs throughout pregnancy.
Date of Response: 24/12/2025
View Response: 10925.pdf

Freedom of Information Request Reference: 10895
Date Received: 28/11/2025
Summary:
Under Freedom of Information can you please advise the cost you attribute to having a hospital bed available ( an average of all disciplines please?) on a 24 hour basis?
Date of Response: 24/12/2025
View Response: 10895.pdf

Freedom of Information Request Reference: 10894
Date Received: 28/11/2025
Summary:
1. Does the aseptic unit at your organisation employ vial-sharing for durvalumab (Imfinzi)? 2. In the past 12 months was durvalumab (Imfinzi) administered as the following actual doses? 1,500 mg 10 mg / kg 20 mg / kg 3. In the past 12 months was durvalumab (Imfinzi) made up for administration to patients at an on-site aseptic unit? 4. In the past 12 months was durvalumab (Imfinzi) made up for administration to patients at an external aseptic unit? 5. Please list the names of external hospitals or hospitals within the Trust that have supplied your organisation with made-up batches of durvalumab (Imfinzi) in the past 12 months. 6. How many patients were treated with durvalumab (Imfinzi) between Jul and Sep 2025, or latest 3 months for which data is available? 7. How many patients were treated with durvalumab (Imfinzi) within each of bands in the national dose banding table between Jul and Sep 2025? 8. How many patients were treated with durvalumab (Imfinzi) for the following types of cancer between Jul and Sep 2025, or latest 3 months for which data is available? Non-small Cell Lung Cancer Biliary Tract Cancer Small Cell Lung Cancer Hepatocellular Carcinoma Endometrial Cancer Muscle Invasive Bladder Cancer Other (please specify) 9. Does the aseptic unit employ vial-sharing for trastuzumab deruxtecan (Enhertu)? 10. In the past 12 months was trastuzumab deruxtecan (Enhertu) administered as the following actual doses? 6.4 mg / kg 5.4 mg / kg 4.4 mg / kg < 4.4 mg / kg 11. In the past 12 months was trastuzumab deruxtecan (Enhertu) made up for administration to patients at an on-site aseptic unit? 12. In the past 12 months was trastuzumab deruxtecan (Enhertu) made up for administration to patients at an external aseptic unit? 13. Please list the names of external hospitals or hospitals within the Trust that have supplied your organisation with made-up batches of trastuzumab deruxtecan (Enhertu) in the past 12 months. 14. How many patients were treated with trastuzumab deruxtecan (Enhertu) within each of bands in the national dose banding table between Jul and Sep 2025?
Date of Response: 24/12/2025
View Response: 10894.pdf

Freedom of Information Request Reference: 10892
Date Received: 27/11/2025
Summary:
1. What is the name of your Medics Appraisals software provider? (None if software not used) 2. What is the name of your second Medics Appraisals software provider? (If you have more than one software provider) 3. When did the contract for your Medics Appraisals software provider start? (dd/mm/yyyy) (None if software not used) 4. When does the contract for your Medics Appraisals software provider expire? (dd/mm/yyyy) (None if software not used) 5. When did the contract for your second Medics Appraisals software provider start? (dd/mm/yyyy) (If you have more than one software provider) 6. When does the contract for your second Medics Appraisals software provider expire? (dd/mm/yyyy) (If you have more than one software provider) 7. What was the Trust's total spend on Medics Appraisals fees in 2024 – not incl. implementation? 8. What was the Trust's total spend on Medics Appraisals fees in 2025 – not incl. implementation?
Date of Response: 23/12/2025
View Response: 10892.pdf

Freedom of Information Request Reference: 10889
Date Received: 27/11/2025
Summary:
Please will you send me a list of Edinburgh schools included in the flu immunisation programme, and the date(s) the vaccine was administered to pupils at each school. Please send this information for 2021, 2022, 2023, 2024 and 2025.
Date of Response: 23/12/2025
View Response: 10889.pdf

Freedom of Information Request Reference: 10888
Date Received: 26/11/2025
Summary:
Can you please provide an update on your Trust’s Infrastructure, including aspects of Networking, Virtualisation, and Cloud? The questions are in the attached spreadsheet, which I would be grateful if you could fill in.
Date of Response: 24/12/2025
View Response: 10888.pdf

Freedom of Information Request Reference: 10884
Date Received: 26/11/2025
Summary:
Please could you provide the following details for any current contract(s). Contract title Start date End date Current supplier Total Contract Value Framework used (if any)
Date of Response: 23/12/2025
View Response: 10884.pdf

Freedom of Information Request Reference: 10883
Date Received: 26/11/2025
Summary:
I wish to make a Freedom of Information Request for the number of patients currently waiting for care at home packages & the combined number of hours.
Date of Response: 24/12/2025
View Response: 10883.pdf

Freedom of Information Request Reference: 10880
Date Received: 25/11/2025
Summary:
I would like to request the following publicly held information relating to the financial accounts of NHS Lothian. • I would like to request the total amount of outstanding debt that is currently owed to NHS Lothian. • I would like to confirm that any such debt is not classed as “accounts payable” and does not accrue interest. • I would like to request the total outstanding value of dept owed to NHS Lothian that exceeds short-term liability of 30 days. • I would like to request how much of this outstanding debt is owed by staff due to overpayments made to them. • I would like to request how much of this debt has been accrued as a result of overseas patients not being charged appropriately for their treatments or care.
Date of Response: 24/12/2025
View Response: 10880.pdf

Freedom of Information Request Reference: 10865
Date Received: 20/11/2025
Summary:
We request under FOISA that you provide, (in a machine readable format, preferably Microsoft Excel or CSV) the following information in respect of suppliers which were not paid in within 30 days for the period starting 1 April 2019 to the date of this request: Supplier Name Invoice Date Invoice Received Date Invoice Due Date Gross Invoice Value Payment Date Payment Terms Late Payment Compensation or Interest Paid (if any)
Date of Response: 24/12/2025
View Response: 10865.pdf

Freedom of Information Request Reference: 10872
Date Received: 24/11/2025
Summary:
Please provide the following information regarding payroll overpayments and pay errors across NHS Lothian, including all staff categories (e.g., clinical, administrative, and executive): 1. The total financial amount (in GBP) lost due to overpayments or pay errors in each of the last five financial years (2020/21 to 2024/25). Please break this down by year.2. A breakdown of the types of overpayments or pay errors contributing to these totals (e.g., incorrect salary grading, overtime miscalculations, duplicate payments, or other categories), including the financial value for each type where possible. 3. The total amount recovered from these overpayments or pay errors in each of the last five financial years (2020/21 to 2024/25), broken down by year. 4. Any internal reports, audits, or policies related to preventing or addressing payroll overpayments/pay errors, published or completed in the last five years (please provide copies or links if available).
Date of Response: 23/12/2025
View Response: 10872.pdf

Freedom of Information Request Reference: 10724
Date Received: 13/10/2025
Summary:
I am requesting the following information held by NHS Lothian concerning oncology treatment delays, cases where Functional Neurological Disorder (FND) was initially diagnosed but later found to be cancer, and discharge safety regarding prophylactic anticoagulation. Time periods requested: • Most recent complete year: 2024 • Ten-year look-back: 2014 (or nearest available year) • Optional: annual breakdown 2020–2024, if available without undue burden ________________________________________ A. Oncology – Biopsy and Treatment Delays 1. Average, median, and maximum turnaround time from biopsy to pathology report. 2. Number of patients whose chemotherapy or treatment schedule was delayed due to biopsy or pathology turnaround. 3. Total number of biopsies processed and number of pathologists and lab technicians on staff during these periods. ________________________________________ B. Neurology / FND Misdiagnosis Impacting Cancer Care 1. Number of patients initially diagnosed with FND who were later confirmed to have cancer. 2. Diagnostic process prior to FND diagnosis, for example in a patient presenting with limited or absent sensation in the lower limbs (paraplegic): o Application of the Three Rules: 1. Rule out structural or organic neurological disease 2. Rule out systemic/metabolic causes 3. Rule out drug/toxin-related causes o Tests that would normally be performed according to standard guidance, including MRI, CT, EMG/nerve conduction studies, blood/metabolic panels, lumbar puncture, and specialist referrals. o Indicate which of these tests are routinely performed prior to confirming FND. 3. Typical steps taken before confirming FND – e.g., referrals, follow-up appointments, monitoring procedures. 4. Delays caused in cancer care: Average, median, and maximum time from initial presentation to: o FND diagnosis o Cancer diagnosis o Start of appropriate treatment 5. Safeguards to prevent misdiagnosis: Policies or standard procedures in place to reduce the risk of incorrectly diagnosing FND when a serious condition such as cancer may be present. ________________________________________ C. Discharge and Blood Thinner Protocols 1. For patients who were immobilised or had limited mobility during a hospital stay (e.g., due to neurological symptoms, misdiagnosed FND, or cancer treatment): o Number of patients discharged without prophylactic anticoagulants (blood thinners) despite being at risk of thromboembolism. o Policies or guidance on prescribing blood thinners at discharge for patients at risk of clots. o Instances where GPs were asked to continue or start prophylactic blood thinners post-discharge, and whether refusals occurred. 2. Any recorded delays or complications (e.g., blood clots) linked to the absence of prophylactic anticoagulation at discharge.
Date of Response: 24/12/2025
View Response: 10724.pdf

Freedom of Information Request Reference: 10119
Date Received: 19/05/2025
Summary:
Under FOI, I am requesting the following: • Total costs incurred for calendar years 2021, 2022, 2023, 2024, and 2025 to the present relating to RAAC remediation, including: o Surveys, investigations, or assessments o Temporary mitigation (e.g. propping, partial closures, relocations) o Repairs, remedial work, or reconstruction o Other associate costs Please also provide a breakdown of cost figures by building type (e.g housing, schools etc) ________________________________________ 3. Total Projected or Estimated Future Costs including but not limited to: • Estimated or projected future costs for the full remediation, removal, or rebuilding of RAAC-affected buildings. • Associated indirect costs (e.g. temporary facilities, decanting, service relocations). • Costs of assessment ________________________________________ 4. Funding and Financial Support • Details of any funding received or allocated specifically for RAAC-related work, including: o Source of funding (e.g. Scottish Government, capital budgets) o Amount and date received 5. Details of any funding requests which have been made but refused (for example to the Scottish Government)
Date of Response: 02/12/2025
View Response: 10119.pdf

Freedom of Information Request Reference: 10954
Date Received: 11/12/2025
Summary:
Request in relation to CCTV footage.
Date of Response: 18/12/2025
View Response: 10954.pdf

Freedom of Information Request Reference: 10918
Date Received: 08/12/2025
Summary:
Q1. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease. Q2. In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products? • Altuvoct • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (standalone) • Hemlibra in combination with any Factor VIII • NovoEight • NovoSeven RT • Nuwiq • Obizur • Refacto AF • Any other products • Marstacimab • Cevenfacta Q3. For patients treated with Advate in the last three months, please provide: • The number of haemophilia A patients treated prophylactically • The number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds) Q4. In the last three months, how many patients were treated with the following products for severe Haemophilia A ONLY? • Altuvoct • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (standalone) • Hemlibra in combination with any Factor VIII • NovoEight • NovoSeven RT • Nuwiq • Obizur • Refacto AF • Any other products • Marstacimab • Cevenfacta
Date of Response: 19/12/2025
View Response: 10918.pdf

Freedom of Information Request Reference: 10913
Date Received: 05/12/2025
Summary:
I notice from the Board’s web site that there has been a service redesign [around May 2025] of part of the Board’s audiology services [https://services.nhslothian.scot/audiology/test/ ]. I am writing to ask the Board to provide me, in accordance with the Freedom of Information legislation, with a copy of the Equality Impact Assessment the Board is required to carry out when redesigning services.
Date of Response: 22/12/2025
View Response: 10913.pdf

Freedom of Information Request Reference: 10902
Date Received: 02/12/2025
Summary:
Question 1. How many patients were treated in the last 4 months (August to November 2025) by the dermatology department with each of the following products: •Abrocitinib •Acitretin •Alitretinoin •Azathioprine •Baricitinib •Ciclosporin •Dupilumab •Lebrikizumab •Methotrexate •Mycophenolate mofetil •Pimecrolimus •Phototherapy (UVB or PUVA) - for Atopic Dermatitis only •Tacrolimus ointment •Tralokinumab •Upadacitinib •Nemolizumab Question 2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department •Abrocitinib •Baricitinib •Dupilumab •Lebrikizumab •Tralokinumab •Upadacitinib •Nemolizumab Question 3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: •6 months to 5 •Age 6-11 •Age 12-17 •Age 18 and above
Date of Response: 19/12/2025
View Response: 10902.pdf

Freedom of Information Request Reference: 10899
Date Received: 01/12/2025
Summary:
For the financial year 2024/25 (April 2024 – March 2025), please provide the following information relating to outsourced reporting services only (excluding any outsourced scanning): 1. What was the total value (£) of radiology reporting work outsourced to private tele-radiology providers? 2. What was the total volume (number of reports) of radiology reporting work outsourced to private tele-radiology providers? 3. Of the outsourced reporting activity, how many were: o MRI reports? o CT reports? o Plain Film reports? 4. Which private tele-radiology companies were used by the Trust during this period? 5. Who holds responsibility within the Trust for overseeing outsourced radiology reporting? Please provide: o Name o Job title o Division/department
Date of Response: 03/12/2025
View Response: 10899.pdf

Freedom of Information Request Reference: 10898
Date Received: 01/12/2025
Summary:
1/What is the required frequency for statutory BLS training? 2/What incentives or measures has the trust adopted to encourage annual BLS training for medical professionals with patient facing duties ( no pay progression if mandatory training not completed, departmental sessions, ESR alerts, managerial supervision of mandatory training etc)? 3/ Does the organisation require resus teams to have Advanced Life Support training?
Date of Response: 19/12/2025
View Response: 10898.pdf

Freedom of Information Request Reference: 10891
Date Received: 27/11/2025
Summary:
Request in relation to personal information.
Date of Response: 27/11/2025
View Response: 10891.pdf

Freedom of Information Request Reference: 10886
Date Received: 26/11/2025
Summary:
Haemophilia A Q1. In the past 12 months [latest 12 months available], how many patients have been diagnosed with the each of the following conditions in your Trust: Haemophilia A Acquired Haemophilia A (AHA) Congenital Haemophilia A with inhibitors CHAwI) Q2. In the last twelve months[latest 12 months available], how many pts with Haemophilia A, have been treated with each of the following products in your Trust: Factor Eight Inhibitor Bypass Activity (FEIBA) Hemlibra (standalone) Hemlibra in combination with NovoSeven RT Hemlibra in combination with Cevenfacta NovoSeven RT Obizur Cevenfacta Q3. In the last twelve months[latest 12 months available], how many patients with Acquired Haemophilia A, have been treated with each of the following products in your Trust: Factor Eight Inhibitor Bypass Activity (FEIBA) NovoSeven RT Obizur Cevenfacta Q4 In the last twelve months[latest 12 months available], how many pts with Congenital Haemophilia A with Inhibitors have been treated with each of the following products in your Trust? Factor Eight Inhibitor Bypass Activity (FEIBA) Hemlibra (standalone) Hemlibra in combination with NovoSeven RT Hemlibra in combination with Cevenfacta Hemlibra in combination with FEIBA Helimbra in combination with Factor VIII NovoSeven RT Obizur Cevenfacta Prothrombin Complex Concentrate (PCC) Q1. What is the total Prothrombin Complex Concentrate usage in International Units (IUs) for your Trust over the last 12 months [latest 12 months available] for each of the products below in your Trust? Prothromplex Beriplex Octaplex Q2: Can you share the Prothrombin Complex Concentrate usage in International Units for your Trust in the last 12 months [latest 12 months available] within each of the following departments, and which PCC is used? Prothromplex Beriplex Octaplex Departments Cardio-speciality General Medicine General surgery Haematology Emergency care Any other
Date of Response: 17/12/2025
View Response: 10886.pdf

Freedom of Information Request Reference: 10885
Date Received: 26/11/2025
Summary:
HAE: Q1. In the past 3 months [latest 3 months available] how many patients have received the following treatments [for any disease]: Berinert (Human C1-esterase inhibitor) Cinryze (Human C1-esterase inhibitor) Orladeyo (Berotralstat) Takhzyro (Lanadelumab) Ruconest (Recombinant human C1-esterase inhibitor) Firazyr (Icatibant injection) Icatibant - any brand except Firazyr IG: Q2. In the past 3 months how many patients have received the following treatment for any disease: Octagam Gamunex Intratect Kiovig Gamten Panzyga Xembify Cuvitru Cutaquig Hyqvia Q3: In the past 3 months, how many patients have received any immunoglobulin treatment for the following diseases: Primary immunodeficiency (PID) Secondary immunodeficiency (SID) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Date of Response: 19/12/2025
View Response: 10885.pdf

Freedom of Information Request Reference: 10882
Date Received: 25/11/2025
Summary:
1. The total amount paid by NHS Lothian in rent and associated fees to the owners or operators of: o The Royal Infirmary of Edinburgh (since its opening at Little France in 2003), and o The Royal Hospital for Sick Children (since its opening at Little France in 2021). 2. Please include any fees or payments made prior to the opening of these hospitals, such as during construction or commissioning phases. 3. Provide a breakdown of the figures by financial year, and if possible, specify: o Rent payments o Service charges or other fees o Any other contractual payments related to the use of these facilities 4. Copies of the contracts or agreements between NHS Lothian and the owners/operators of these hospitals, including any variations or amendments made since the original agreements.
Date of Response: 19/12/2025
View Response: 10882.pdf

Carer Positive Icon
Awards Aware Icon
We are a Living wage Employer Icon
Duke of Edinburgh's Award Logo
Young Person's Guaranteed Employer Logo
Scottish Top Employers Logo
Disability Confident Employer Logo